We are live on ! Find out more
VIA

Vident Investment Advisory Portfolio holdings

AUM $2.9B
1-Year Est. Return 24.67%
This Fund
S&P 500
This Quarter Est. Return
+1.13%
1 Year Est. Return
+24.67%
3 Year Est. Return
+82.63%
5 Year Est. Return
+113.33%
10 Year Est. Return
AUM
$2.46B
AUM Growth
+$238M
Cap. Flow
+$217M
Cap. Flow %
8.81%
Top 10 Hldgs %
17.01%
Holding
976
New
195
Increased
478
Reduced
214
Closed
88

Sector Composition

Rank Sector Weight
1 Technology 28.44%
2 Industrials 13.87%
3 Healthcare 11.83%
4 Consumer Discretionary 8.52%
5 Financials 6.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CTMX icon
301
CytomX Therapeutics
CTMX
$754M
$2.17M 0.09%
79,143
+21,500
+37% +$614K
AKAM icon
302
Akamai
AKAM
$15.9B
$2.14M 0.09%
29,901
+25,593
+594% +$1.74M
BWA icon
303
BorgWarner
BWA
$13.9B
$2.13M 0.09%
45,004
-26,632
-37% -$1.24M
HK
304
DELISTED
Halcon Resources Corporation
HK
$2.12M 0.09%
408,841
+15,337
+4% +$104K
KLIC icon
305
Kulicke & Soffa
KLIC
$4.78B
$2.1M 0.09%
80,911
-65,105
-45% -$1.57M
AGEN
306
Agenus
AGEN
$290M
$2.1M 0.09%
24,707
+6,635
+37% +$589K
XONE
307
DELISTED
The ExOne Company
XONE
$2.08M 0.08%
277,348
-189,509
-41% -$1.7M
JRI icon
308
Nuveen Real Asset Income & Growth Fund
JRI
$352M
$2.06M 0.08%
+126,258
New +$2.14M
META icon
309
Meta Platforms (Facebook)
META
$1.51T
$1.98M 0.08%
12,036
-144
-1% -$25.9K
ECHO
310
EchoStar
ECHO
$26.2B
$1.98M 0.08%
44,472
+6,546
+17% +$312K
TWTR
311
DELISTED
Twitter, Inc.
TWTR
$1.97M 0.08%
68,714
+7,285
+12% +$214K
INO icon
312
Inovio Pharmaceuticals
INO
$69M
$1.96M 0.08%
33,195
+8,886
+37% +$481K
ACH
313
Accendra Health
ACH
$214M
$1.95M 0.08%
122,659
+19,095
+18% +$340K
ED icon
314
Consolidated Edison
ED
$39.9B
$1.91M 0.08%
24,577
+3,926
+19% +$305K
WSO icon
315
Watsco Inc
WSO
$13.6B
$1.89M 0.08%
10,145
+2,732
+37% +$474K
AZN icon
316
AstraZeneca
AZN
$250B
$1.89M 0.08%
26,477
+7,724
+41% +$535K
CLLS
317
Cellectis
CLLS
$285M
$1.89M 0.08%
61,797
+16,788
+37% +$530K
DG icon
318
Dollar General
DG
$27.9B
$1.88M 0.08%
19,322
+1,893
+11% +$182K
PVLA
319
Palvella Therapeutics
PVLA
$2.27B
$1.86M 0.08%
3,595
+963
+37% +$596K
T icon
320
AT&T
T
$163B
$1.85M 0.08%
68,485
-12,226
-15% -$340K
BLCM
321
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.83M 0.07%
20,526
+5,483
+36% +$414K
HST icon
322
Host Hotels & Resorts
HST
$16B
$1.81M 0.07%
+93,214
New +$1.82M
NXPI icon
323
NXP Semiconductors
NXPI
$60.4B
$1.8M 0.07%
15,957
-3,084
-16% -$372K
JKHY icon
324
Jack Henry & Associates
JKHY
$11.1B
$1.79M 0.07%
14,723
+2,894
+24% +$352K
KDP icon
325
Keurig Dr Pepper
KDP
$40.8B
$1.77M 0.07%
14,657
-1,231
-8% -$136K

Similar funds

Vident Investment Advisory's Q1 2018 Portfolio in Review

As of Q1 2018, Vident Investment Advisory held 976 positions worth $2.46B, up 11% from $2.22B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Vident Investment Advisory deployed $217M of net new capital in Q1 2018, opening 195 new positions and adding to 478 existing holdings. Its largest new stake was NexPoint Diversified Real Estate Trust: 340,420 shares worth $7.83M.

By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 26% a quarter earlier, followed by Industrials and Healthcare.

On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $59.4M trimmed.

  • Vident Investment Advisory's largest Q1 2018 buy was NexPoint Diversified Real Estate Trust: 340,420 shares worth $7.83M.
  • Vident Investment Advisory added most to Cognex in Q1 2018, an estimated $18.8M increase.
  • Vident Investment Advisory's biggest Q1 2018 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $59.4M.
  • Vident Investment Advisory fully exited Eaton Vance Tax-Advantaged Global Dividend Income Fund in Q1 2018, selling an estimated $10.7M.
  • Vident Investment Advisory's ten largest holdings make up 17% of its $2.46B portfolio in Q1 2018.
  • Vident Investment Advisory opened 195 new positions and closed 88 in Q1 2018.
  • Vident Investment Advisory's portfolio value rose 11% quarter-over-quarter to $2.46B.

Based on Vident Investment Advisory's 13F filing for Q1 2018, filed 14 May 2018.